91224-37-2

中文名称 (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P

英文名称 D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE

CAS 91224-37-2

分子式 C75H108N20O13

分子量 1497.79

MOL 文件 91224-37-2.mol

更新日期 2024/10/20 11:23:30

91224-37-2 结构式

基本信息物理化学性质安全数据 (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P价格(试剂级) 常见问题列表

基本信息

中文别名

化合物 T20413
D-ARG1,D-TRP7,9,LEU11]神经肽P物质

英文别名

SPANTIDE
SPANTIDE I
(D-Arg1,D-Trp7
SPANTIDE HYDROCHLORIDE
M.W. 1497.80 C75H108N20O13
1-Arg-7,9-Trp-11-Leu-substance p
(D-ARG1,D-TRP7,9,LEU11)-SUBSTANCE P
[D-Arg1,D-Trp7,9,L-Leu11]substance P
Substance p, Arg(1)-Trp(7,9)-Leu(11)-
SUBSTANCE P, [D-ARG1, D-TRP7,9, LEU11]

物理化学性质

密度1.43±0.1 g/cm3(Predicted)

储存条件−20°C

酸度系数(pKa)13.31±0.20(Predicted)

形态粉末

颜色White to off-white

水溶解性Soluble to 1 mg/ml in water

安全数据

WGK Germany3

(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/08/19	HY-P1194	(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I	91224-37-2	1 mg	550元
2024/08/19	HY-P1194	(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I	91224-37-2	5 mg	1650元
2024/08/19	HY-P1194	(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I	91224-37-2	10 mg	2450元

常见问题列表

生物活性

Spantide I 是substance P 的类似物，是选择性的神经激肽-1 受体 (NK1 receptor) 的拮抗剂，其对NK1 和 NK2 受体的 Ki 值分别为 230 nM 和 8150 nM。Spantide I 可减少感染角膜的1型细胞因子和增强2型细胞因子 IL-10，从而显著减少角膜穿孔。

靶点

NK1

230 nM (Ki)

NK2

8150 nM (Ki)

体内研究

Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals.
Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β.

Animal Model:	Female, 8-week-old C57BL/6 (B6) and BALB/c mice.
Dosage:	36 μg/mouse.
Administration:	IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection).
Result:	At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi.